Cara Therapeutics | CARA - PE Price to Earnings


Cara Therapeutics reported 0.49 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Cara Therapeutics 0.49 27.28 Mar/2026
Chugai Pharma 21.73 2.58 Sep/2026
Cipla 38.39 2.57 Sep/2026
Clal Biotechnology 11.67 2.62 Dec/2022
Compugen 5.58 0.12 Jun/2026
CSL 16.16 9.59 Dec/2025
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 16.12 3.61 Sep/2026
J&J 25.86 3.57 Sep/2026
Neurocrine Biosciences 83.17 61.07 Sep/2026
Pacira 80.9 45.22 Sep/2026
Pfizer 15.2 3.72 Sep/2026
RedHill Biopharma 0.04 0.03 Jun/2025
Supernus Pharmaceuticals 72.26 6.89 Sep/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023